Firefly Neuroscience CEO Issues Letter to Stockholders Following Closing of Merger and Listing on Nasdaq

AI Technology to Assist Clinicians to Drive Better Outcomes in Brain Health

TORONTO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders, today issued a letter to its stockholders from its Chief Executive Officer, Jon Olsen, following the closing of its merger transaction with WaveDancer, Inc. (NASDAQ: WAVD).

Mr. Olsen and David Johnson, Executive Chairman, encourage stockholders to view this video message and investor presentation regarding the global brain health problem today and Firefly’s vision for the future.

Dear Fellow Firefly Stockholders,

This week’s closing and the addition of working capital puts us in a position to execute on our strategic objectives.   This is an extraordinary milestone for us and our stockholders. Firefly is focused on using AI to bring objective assessment of brain function to the front lines of healthcare. We are dedicated to improving outcomes for people suffering with brain health illnesses and disorders such as dementia and depression. The right diagnosis and treatment, the first time, is something that drives us forward at Firefly.

We plan to execute upon two key strategic pathways to support better outcomes. First, the commercialization of our FDA-cleared Brain Network Analytics (BNA) technology to neurologists in the United States, and second, partnering with Central Nervous System (“CNS”) drug companies to advance the development of new treatments for people with brain health disorders and illnesses.

Firefly’s BNA arrives at a critical time to help clinicians looking for innovative technologies that can provide an objective understanding of how the brain is functioning. BNA reinforces precise and timely diagnosis, and the optimization of patient care pathways. In fact, real world use of BNA in the United States has shown that when BNA is part of a patient care plan, patients required fewer medication changes, recovered faster, and were more compliant with their treatment. ¹ Based on these promising results, we are very excited to make BNA commercially available to neurologists in 2025.